Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a pioneering biotechnology company dedicated to improving lives by developing precision-engineered medicines to silence diseases, provided updates on the SLN360 and SLN124 programs during a presentation at the 41st Annual J.P. Morgan Healthcare Conference. With their innovative approach and extensive experience, Silence Therapeutics is striving to make a positive impact on the world.
SLN360 for cardiovascular disease
- The SLN360 phase 2 study has made a groundbreaking start, with the first participants receiving treatment for high-risk atherosclerotic cardiovascular disease (ASCVD). The Company is aiming to complete the study’s enrollment by the fourth quarter of 2023, making this a major milestone in the field of cardiovascular disease research.
- Silence is eagerly anticipating the data from the phase 1 multiple dose study on subjects with high Lp(a) and stable ASCVD, which is expected to be released in the fourth quarter of 2023. Excitingly, in the single dose study conducted on healthy volunteers with high Lp(a), the 300 mg and 600 mg doses of SLN360 were found to reduce median maximal Lp(a) levels by an impressive 96% and 98%, respectively.
SLN124 for hematological diseases
- Are you living with polycythemia vera (“PV”)? If so, you may be eligible to participate in the SLN124 phase 1/2 study! This two-part study includes a phase 1 open-label, dose finding study, as well as a phase 2 randomized, double-blind, placebo-controlled parallel arm study. Enrollment is now open – don’t miss this chance to contribute to groundbreaking research!
- We are eagerly awaiting the data from the phase 1 multiple dose study of SLN124 in thalassemia patients, which is projected to be available in the fourth quarter of 2023. This exciting study will provide valuable insight into the potential of this promising drug to improve the lives of those suffering from this debilitating condition.
Silence is gearing up for a momentous year in 2023, with dosing already initiated in the SLN360 phase 2 ASCVD study and the SLN124 PV study just getting off the ground. President and CEO Craig Tooman is highly optimistic about the prospects of their mRNAi GOLD™ platform and is thrilled about the reception the SLN360 program has been getting. He’s eager to share further updates on their progress as the year progresses.
About Silence Therapeutics
Silence Therapeutics is revolutionizing the way diseases are treated through its innovative mRNAi GOLD™ platform. This cutting-edge technology uses RNA interference to silence specific target genes that are thought to play a role in the pathology of diseases with significant unmet needs. Silence’s wholly owned product candidates, SLN360 and SLN124, are designed to reduce cardiovascular risk and address rare hematological diseases respectively. Additionally, Silence has ongoing collaborative research and development agreements with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. By embracing the power of RNAi, Silence is paving the way for a new generation of medicines.
The future looks bright for the Company as they anticipate clinical and commercial success, regulatory approvals of their product candidates, and potential partnerships and collaborations. However, it is important to note that these forward-looking statements are based on the Company’s current assumptions, beliefs, expectations, estimates, and projections. Factors such as unanticipated events, risks, and uncertainties may cause actual outcomes to differ from what is expressed or forecasted. Therefore, security holders and prospective security holders should exercise caution when relying on these forward-looking statements. The Company will continue to monitor the situation and update any relevant information as needed.